These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102. Incidence and Time-to-Onset of Carbapenemase-Producing Enterobacterales (CPE) Infections in CPE Carriers: a Retrospective Cohort Study. Hoellinger B; Deboscker S; Danion F; Lavigne T; Severac F; Ruch Y; Ursenbach A; Lefebvre N; Boyer P; Hansmann Y Microbiol Spectr; 2022 Dec; 10(6):e0186822. PubMed ID: 36321906 [TBL] [Abstract][Full Text] [Related]
103. Identification and Preliminary Hierarchisation of Selected Risk Factors for Carbapenemase-Producing Enterobacteriaceae (CPE) Colonisation: A Prospective Study. Timler M; Timler W; Bednarz A; Zakonnik Ł; Kozłowski R; Timler D; Marczak M Int J Environ Res Public Health; 2023 Jan; 20(3):. PubMed ID: 36767330 [TBL] [Abstract][Full Text] [Related]
104. Closing the Brief Case: IMP, the Uncommonly Common Carbapenemase. Lowe CF; Matic N; Champagne S; Romney MG; Leung V; Ritchie G J Clin Microbiol; 2020 Mar; 58(4):. PubMed ID: 32213573 [No Abstract] [Full Text] [Related]
105. The Brief Case: IMP, the Uncommonly Common Carbapenemase. Lowe CF; Matic N; Champagne S; Romney MG; Leung V; Ritchie G J Clin Microbiol; 2020 Mar; 58(4):. PubMed ID: 32213572 [No Abstract] [Full Text] [Related]
106. IMP-6 Carbapenemase-Producing Enterobacteriaceae Bacteremia Successfully Treated with Amikacin-Meropenem in Two Patients. Nakakura I; Ogawa Y; Sakakura K; Imanishi K; Hirota K; Shimatani Y; Uehira T; Nakamori S; Sako R; Doi T; Yamazaki K Pharmacotherapy; 2017 Oct; 37(10):e96-e102. PubMed ID: 28699652 [TBL] [Abstract][Full Text] [Related]
107. Comparison between IMP carbapenemase-producing Enterobacteriaceae and non-carbapenemase-producing Enterobacteriaceae: a multicentre prospective study of the clinical and molecular epidemiology of carbapenem-resistant Enterobacteriaceae. Hayakawa K; Nakano R; Hase R; Shimatani M; Kato H; Hasumi J; Doi A; Sekiya N; Nei T; Okinaka K; Kasahara K; Kurai H; Nagashima M; Miyoshi-Akiyama T; Kakuta R; Yano H; Ohmagari N J Antimicrob Chemother; 2020 Mar; 75(3):697-708. PubMed ID: 31789374 [TBL] [Abstract][Full Text] [Related]
108. Epidemiological, clinical, and microbiological characteristics of carbapenemase-producing Enterobacteriaceae bloodstream infection in the Republic of Korea. Park JW; Lee H; Park SY; Kim TH Antimicrob Resist Infect Control; 2019; 8():48. PubMed ID: 30873279 [TBL] [Abstract][Full Text] [Related]
109. Clinical and Microbiological Characteristics of Bacteremia Caused by Carbapenemase-producing Enterobacterales in Minami Ibaraki Area, Japan. Uchida M; Terada N; Saito K; Ishikawa H; Funayama Y; Oishi T; Shinohara H; Ebihara T; Kurihara Y; Hitomi S J Microorg Control; 2024; 29(2):81-89. PubMed ID: 38880620 [TBL] [Abstract][Full Text] [Related]
110. Clinical characteristics and treatment of IMP-type carbapenemase-producing Enterobacteriaceae bacteremia: Case series and literature review. Soneda K; Uda K; Araki K; Murakoshi T; Yuza Y; Saito O; Kinoshita K; Higuchi H; Horikoshi Y J Infect Chemother; 2023 Jan; 29(1):26-32. PubMed ID: 36100144 [TBL] [Abstract][Full Text] [Related]
111. Global dissemination of extensively drug-resistant carbapenemase-producing Enterobacteriaceae: clinical perspectives on detection, treatment and infection control. Tängdén T; Giske CG J Intern Med; 2015 May; 277(5):501-12. PubMed ID: 25556628 [TBL] [Abstract][Full Text] [Related]
112. Evolution of carbapenemase-producing Enterobacteriaceae at the global and national level: what should be expected in the future? Oteo J; Miró E; Pérez-Vázquez M; Navarro F Enferm Infecc Microbiol Clin; 2014 Dec; 32 Suppl 4():17-23. PubMed ID: 25542048 [TBL] [Abstract][Full Text] [Related]